Statement on the Benefit Assessment of Etrasimod (ulcerative Colitis, ≥ 16 Years)

被引：0
|
作者：
Jansen, Petra Lynen
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2024年 / 62卷 / 10期
关键词：
INFLAMMATORY-BOWEL-DISEASE; CORTICOSTEROID-THERAPY; ECCO GUIDELINES; THERAPEUTICS;
D O I：
10.1055/a-2414-9330
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1857 / 1861
页数：5
相关论文
共 50 条
  • [1] Ulcerative colitis Etrasimod approved from the Age of 16
    Warpakowski, Andrea
    VISCERAL MEDICINE, 2024, 40 (03)
  • [2] Etrasimod for ulcerative colitis
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (05): : 405 - 405
  • [3] Etrasimod for ulcerative colitis
    Brierley, Rob
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (08): : 708 - 708
  • [4] Etrasimod (Velsipity) for Ulcerative Colitis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2023, 65 (1690): : 187 - 189
  • [5] Etrasimod for the treatment of ulcerative colitis
    Wils, Pauline
    Peyrin-Biroulet, Laurent
    IMMUNOTHERAPY, 2023, 15 (05) : 311 - 321
  • [6] Etrasimod for ulcerative colitis: evaluating phase III results
    Matsuoka, Katsuyoshi
    Hibi, Toshifumi
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2023, 20 (12) : 762 - 763
  • [7] Statement on the benefit assessment procedure for the active substance upadacitinib (new indication: ulcerative colitis, previously treated) Statement on general aspects
    Bokemeyer, Bernd
    Siegmund, Britta
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2023, 61 (02): : 205 - 210
  • [8] Hepatic Impact of Etrasimod for Treatment of Moderately to Severely Active Ulcerative Colitis: An Integrated Safety Summary From the Etrasimod Ulcerative Colitis Clinical Program
    Regueiro, Miguel
    Vermeire, Severine
    Rubin, David T.
    Dubinsky, Marla C.
    Hart, Ailsa
    Wu, Joseph
    Green, Jesse
    Woolcott, John C.
    Gorelick, Kenneth J.
    McDonnell, Aoibhinn
    Lazin, Krisztina
    Peyrin-Biroulet, Laurent
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S816 - S817
  • [9] Etrasimod for ulcerative colitis: evaluating phase III results
    Katsuyoshi Matsuoka
    Toshifumi Hibi
    Nature Reviews Gastroenterology & Hepatology, 2023, 20 : 762 - 763
  • [10] Impact of Etrasimod on Blood Pressure and Hypertension: Data From the Etrasimod Ulcerative Colitis Clinical Program
    Vermeire, Severine
    Rubin, David T.
    Peyrin-Biroulet, Laurent
    Dubinsky, Marla C.
    Regueiro, Miguel
    Irving, Peter M.
    Goetsch, Martina
    Lazin, Krisztina
    Wu, Joseph
    Modesto, Irene
    Woolcott, John C.
    McDonnell, Aoibhinn
    Rabbat, Christopher J.
    Yarur, Andres J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S675 - S675
12345